Enterprise Value
16.41M
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
0.17%
Insider Ownership
5.57%
Institutional Own.
13.53%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zygel (ZYN002 CBD Gel) Details Genetic disorder, Rare genetic disease, Fragile X syndrome | Phase 3 Data readout | |
Zygel (ZYN002 CBD Gel) Details Genetic disorder, Rare genetic disease, Deletion Syndrome | Phase 3 Initiation | |
Zygel (ZYN002 CBD Gel) Details Epilepsy | Failed Discontinued | |
Zygel (ZYN002 CBD Gel) Details Autism spectrum disorders | Failed Discontinued |